Development of a technique for specific labelling phagosome-derived membranous structures in dendritic cells

开发树突状细胞中特异性标记吞噬体衍生膜结构的技术

基本信息

  • 批准号:
    10508764
  • 负责人:
  • 金额:
    $ 7.11万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-01 至 2024-07-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY/ABSTRACT Dendritic cells (DCs) are immune cells that play a critical role in establishing adaptive immunity through a process termed cross-presentation. A major route of cross-presentation starts with the phagocytosis of a particulate pathogen by a DC into an intracellular vacuole called phagosome. The phagosome is a site for assembling major histocompatibility complex class 1 (MHC-I) and antigenic peptides into MHC-I:peptide complexes and initiating the transport of the MHC-I:peptide complexes to the cell surface. How the MHC-I:peptide complexes are transported from the phagosome to the cell surface is not well understood but probably through shedding membranous structures by the phagosome. However, existing live-cell imaging techniques cannot provide a comprehensive picture of this process. The long-term goal of this proposed research is to develop a new technique capable of specifically labelling all membranous structures derived from a pathogen-containing phagosome in a DC undergoing cross-presentation. This proposed technique uses highly engineered microparticles crafted to mimic particulate pathogens while carrying a releasable membrane dye. The most innovative feature of this proposed technique is the use of a special material to first hold the dye in the microparticle before the microparticle is phagocytosed and then release the dye after the phagocytosis. The central hypothesis of this study is that by delivering a membrane dye solely into a phagosome with a microparticle and rendering the dye releasable from the microparticle, the membranous structures derived from the phagosome can be stained by the dye. This hypothesis has been formulated on the basis of our own preliminary results. The objective of this application, which is the next step toward attainment of the long- term goal, is to determine whether the microparticles can be used to specifically label phagosome-derived membranous structures in model DCs. The specific aims are to (1) establish a protocol for fabricating the microparticles, and (2) determine whether the microparticles can be phagocytosed by model DCs and whether the microparticle-laden phagosome can disseminate membranous structures stained by the dye. Success of this project will prove the feasibility of this technique and lay a foundation for its further development. The fully developed version of this technique promises to significantly advance our understanding of cross-presentation.
项目摘要/摘要 树突状细胞(Dendritic cells,DCs)是一种在获得性免疫中起关键作用的免疫细胞 通过一个叫做交叉呈现的过程。交叉展示的一个主要途径是从 颗粒状病原体被DC吞噬到称为吞噬体的细胞内空泡中。的 吞噬体是组装主要组织相容性复合物1类(MHC-I)和抗原性复合物1类(MHC-II)的位点。 肽复合物,并启动MHC-I:肽复合物转运至 细胞表面。MHC-I:肽复合物如何从吞噬体转运到细胞 表面不太清楚,但可能是通过吞噬体脱落膜结构。 然而,现有的活细胞成像技术不能提供这一过程的全面图片。 这项研究的长期目标是开发一种新的技术, 标记来自DC中含有病原体的吞噬体的所有膜结构, 交叉展示这项拟议中的技术使用高度工程化的微粒, 颗粒病原体,同时携带可释放的膜染料。最具创新性的特点是, 所提出的技术是使用一种特殊的材料,首先将染料保持在微粒中, 微粒被吞噬,然后在吞噬后释放染料。核心假设 这项研究的一个重要方面是,通过将膜染料单独递送到具有微粒的吞噬体中, 使染料可从微粒释放,从微粒衍生的膜结构 吞噬体可以被染料染色。这一假设是根据我们自己的 初步结果。本申请的目的,这是实现长期目标的下一步- 术语目标是确定微粒是否可以用于特异性标记吞噬体来源的 模型DC中的膜结构。具体目标是(1)建立一个用于制造 (2)确定微粒是否可以被模型DC吞噬, 载有微粒的吞噬体是否可以散布被染料染色的膜结构。 该项目的成功将证明该技术的可行性,并为该技术的进一步推广奠定基础 发展这项技术的完全开发版本有望显着推进我们的 理解交叉呈现。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jingjiao Guan其他文献

Jingjiao Guan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jingjiao Guan', 18)}}的其他基金

Development of a technique for specific labelling phagosome-derived membranous structures in dendritic cells
开发树突状细胞中特异性标记吞噬体衍生膜结构的技术
  • 批准号:
    10665759
  • 财政年份:
    2022
  • 资助金额:
    $ 7.11万
  • 项目类别:
Development of a Microdevice for Photoelectrical Stimulation of Cells
细胞光电刺激微型装置的开发
  • 批准号:
    10263886
  • 财政年份:
    2020
  • 资助金额:
    $ 7.11万
  • 项目类别:

相似海外基金

Tri-Signal Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的三信号人工抗原呈递细胞
  • 批准号:
    10751133
  • 财政年份:
    2023
  • 资助金额:
    $ 7.11万
  • 项目类别:
Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer Immunotherapy
用于癌症免疫治疗的微流控精密工程人工抗原呈递细胞
  • 批准号:
    10696138
  • 财政年份:
    2022
  • 资助金额:
    $ 7.11万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10663066
  • 财政年份:
    2022
  • 资助金额:
    $ 7.11万
  • 项目类别:
The role of microglia as antigen presenting cells in Globoid Cell Leukodystrophy
小胶质细胞作为抗原呈递细胞在球状细胞脑白质营养不良中的作用
  • 批准号:
    10537159
  • 财政年份:
    2022
  • 资助金额:
    $ 7.11万
  • 项目类别:
Analysis of the function of antigen-presenting cells present in the stroma of colorectal cancer and the intracellular microbiome
结直肠癌基质中抗原呈递细胞和细胞内微生物组的功能分析
  • 批准号:
    21K08723
  • 财政年份:
    2021
  • 资助金额:
    $ 7.11万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10156950
  • 财政年份:
    2021
  • 资助金额:
    $ 7.11万
  • 项目类别:
The role of CX3CR1+ antigen presenting cells in T cell selection and central tolerance"
CX3CR1抗原呈递细胞在T细胞选择和中枢耐受中的作用"
  • 批准号:
    10631854
  • 财政年份:
    2021
  • 资助金额:
    $ 7.11万
  • 项目类别:
Reprogramming Cancer Cells into Antigen Presenting Cells: Cancer Vaccination with mRNA Enabled by Charge-Altering Releasable Transporters
将癌细胞重编程为抗原呈递细胞:通过改变电荷的可释放转运蛋白实现 mRNA 的癌症疫苗接种
  • 批准号:
    10153927
  • 财政年份:
    2021
  • 资助金额:
    $ 7.11万
  • 项目类别:
Class II artificial antigen presenting cells for cancer immunotherapy
用于癌症免疫治疗的 II 类人工抗原呈递细胞
  • 批准号:
    10331830
  • 财政年份:
    2021
  • 资助金额:
    $ 7.11万
  • 项目类别:
Analysis on detrimental interplay between pathogenic helper T cells, inflammatory antigen-presenting cells and disease-associated microglia in chronic pathogenesis of multiple sclerosis
多发性硬化症慢性发病机制中致病性辅助 T 细胞、炎症抗原呈递细胞和疾病相关小胶质细胞之间的有害相互作用分析
  • 批准号:
    20K16294
  • 财政年份:
    2020
  • 资助金额:
    $ 7.11万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了